View source for ZD4054

== ZD4054 ==

'''ZD4054''' (/zɛd fɔːr oʊ faɪv fɔːr/), also known as '''Zibotentan''', is a specific [[endothelin receptor antagonist]] that was under development for the treatment of [[metastatic]] [[castration-resistant prostate cancer]] (mCRPC). 

=== Etymology ===

The name '''ZD4054''' is a systematic code assigned by the developing company, [[AstraZeneca]]. The prefix 'ZD' is commonly used in the naming of drugs developed by this company. The numbers '4054' do not have a known specific meaning.

=== Mechanism of Action ===

ZD4054 works by blocking the [[endothelin-1]] receptors (ET_A). Endothelin-1 is a potent vasoconstrictor and has been implicated in the progression of cancer. By blocking these receptors, ZD4054 inhibits the action of endothelin-1, potentially slowing the growth and spread of cancer cells.

=== Clinical Trials ===

ZD4054 underwent Phase II and III [[clinical trials]] for the treatment of mCRPC. However, the drug did not meet its primary endpoint of improving overall survival in patients with mCRPC and development was discontinued.

=== Related Terms ===

* [[Endothelin receptor antagonist]]
* [[Metastatic]]
* [[Castration-resistant prostate cancer]]
* [[Clinical trials]]
* [[AstraZeneca]]

[[Category:Pharmaceuticals]]
[[Category:Prostate cancer]]
[[Category:Clinical trials]]
[[Category:Endothelin receptor antagonists]]

{{dictionary-stub}}